ABSTRACT
In recent years recognition of the potential clinical benefits from activating the innate immune system has increased. Toll-like receptor 9 (TLR9) can be readily activated with synthetic CpG oligodeoxynucleotides (ODNs) that have become widely used both as research tools and in the development of novel therapeutics for the treatment of cancers and infectious and allergic diseases. This chapter will summarize the immune effects and early clinical results of these novel classes of drug candidates.
